李环球

姓　　名：李环球

职称职务：教授,博士生导师

电子邮箱：huanqiuli@suda.edu.cn

办公地址：云轩楼1324

个人简介：

苏州大学教授，博导，药物化学系副主任。主要从事药物化学生物学与人工智能药物的研究，集中在免疫炎症和肿瘤免疫治疗新靶标的发现及药物研发。先后承担国家自然科学基金重大项目课题子课题1项，面上及青年项目3项、江苏省自然科学基金等省部级项目3项、国家博士后项目2项，市厅级及企事业横向合作项目8项。以第一作者或通讯作者在Eur Heart J、Nat Commun、Acta Pharm Sin B、Pharmacol Ther、J Adv Res、J Med Chem、Cell Death Dis、Eur J Med Chem、Phytomedicine等中科院一区TOP期刊发表科研论文80余篇,其中影响因子大于10论文11篇，申请国际及国家发明专利17项，获授权14项，转让专利3项，其中一项抗痛风新药专利以2000万的金额成功转化。以第二完成人获得教育部自然科学技术二等奖一项，省自然科学三等奖一项。曾指导学生获得2021中国国际互联网+创新创业大赛铜奖，2022年江苏省优秀硕士学位论文。

一、学习工作经历

1、学历背景：

2004.9－2008.9 南京大学生命科学院,硕博连读,理学博士

2000.9－2004.7 吉林大学生物与农业工程学院,工学学士

2、工作经历：

2011.3－今苏州大学医学部药学院，副教授、教授

2014.3－2015.5  美国新墨西哥大学化学与化学生物系，访问学者

2008.9 -2010.12 南京大学化学化工学院，博士后

二、研究方向

（1）人工智能药物设计

（2）抗炎免疫小分子药物研发

（3）天然活性化合物智能筛选及靶标挖掘

（4）多肽及核素偶联药物设计

三、近五年科研项目

1. 国家自然科学基金重大项目课题子课题，22595461，基于调控“未病”指征的生理活性物质的快速生物制造与应用（建库），2026/01-2030/12，125万。

2. 国家自然科学基金面上项目，82373725，新型抗动脉粥样硬化P2Y6R选择性抑制剂的设计、优化及作用机制研究，2024/01-2027/12，49万。

3. 国家实验室新药研发课题，抗动脉粥样硬化原创靶标候选药物开发，2026/1-2027/12， 186万，合作承担。

4. 企业委托开发项目：靶向嘌呤受体的痛风药物及透皮制剂技术研发，2025.01-2027.01，110万元，排名第二。

5. 苏州市科技计划, 医疗卫生科技创新, SKY2022103, FUT8作为转移型结直肠癌治疗靶标的确证及小分子靶向药物的研发, 2022/07-2025/06, 5万。

6. 企业委托开发项目：一种小分子-蛋白结合力评价方法的开发，H220356, 2022/1-2024/12, 41万，在研, 主持  

7. 企业委托开发项目：治疗急性痛风性关节炎的小核酸药物开发及动物模型活性评价，H220070,2022/1-2023/12, 53万，主持

8. 国家自然科学基金面上项目，81773745，P2Y14R对急性痛风性关节炎的调控作用及先导化合物的靶向干预机制研究，2018/01-2021/12，61.5万。

9. 江苏省肿瘤小分子靶向治疗及伴随诊断工程研究中心开放课题项目，SKY2022103, 新型 FUT8 小分子抑制剂的设计、靶向性研究及其作为转移型结肠癌治疗药物的开发, 2024/07-2026/06, 5万元。

10. 江苏省自然科学基金面上项目，BK20181437, XOD-NLRP3双重抑制剂的设计合成及其作为痛风治疗药物的研究，2018/01-2021/12, 10万，主持。

四、近三年代表性论文

1. Leilei Zong, Zhoudong Zhang, Xionghao Li, Jie Jia, Xiaohui Jiang, Zitong Wang, Wenlang Liu, Xinyi Shen, Xiangyang Feng, Yangqing Huang, Haifeng Ding, Yunsong Song, Zheng Zheng,* Jiandong Yuan,* Huanqiu Li*.Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025, 68, 14907-14918.一区top期刊IF:7.8

2. Weipeng Yong, Shu Zhang, Zhoudong Zhang, Zhihao Li, Yu Qin, Xunhao Qi, Dong Wang,Yujuan Zhang,* Jianguo Li,* Zhiyong Liu, Ran Zhu, Huanqiu Li,* Guanglin Wang* Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer. J Med Chem. 2025, 68, 17794-17807.一区top期刊IF:7.8

3. Sheng Tian, Kai Wang, Chunxiao Liu, Xiaotian Kong, Shufan Ren, Huanqiu Li*. Computational Discovery and Repurposing of Chloramphenicol Succinate as a Potent P2Y14 Receptor Antagonist for Inflammatory Bowel Disease Therapy. J Adv Res. 2025, /doi.org/10.1016/j.jare.2025.08.035. 一区top期刊IF:13

4. Chencheng Li, Hui Wang, Li Liu, Chunxiao Liu, Yiyun Wang, Li Yin, Yalian Yang, Sheng Tian*, Jialong Qian, Mengze Zhou*, Huanqiu Li*, Qinghua Hu*. Discovery of Novel P2Y14R Inhibitors for Ameliorating Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation. J Med Chem. 2025, 68, 23277–23299.一区top期刊IF:7.8

5. Yin L, Ni KX, Mao TQ, Tian S, Liu CX, Chen JY, Zhou MZ, Li HQ*, Hu QH*.Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors. Pharmacol Ther 2025, 267, 108802. 一区top期刊IF:12

6. Tianqi Mao, Jingjing Gao, Jie Jia, Fengxia Zou, Kai Wang, Yiyun Wang, Jiyu Li, Tao Shen,Huanqiu Li* Small-molecule inhibitors in psoriasis: medicinal chemistry insights. Expert. Opin. Drug. Dis. 2025, 20, 891-912.                          

7. Hui Wang ,Li Liu ,Zhoudong Zhang, Chencheng Li, Kai Wang, Jingjing Gao, Qinghua Hu, Weipeng Wang ,Huanqiu Li*. Insights of affinity-based probes for target identification in drug discovery. Eur J Med Chem 2025, 293, 117711.

8. Yanshuo Guo, Tianqi Mao, Yafei Fang, Hui Wang, Jiayue Yu, Yifan Zhu, Shige Shen, Mengze Zhou, Huanqiu Li*, Qinghua Hu*.Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics. J Adv Res 2025, 69, 427-488. 一区top期刊IF:13

9. Liu CX, Wang H, Han L, Zhu YF, Ni SR, Zhi JK, Yang XP, Zhi JY, Tian S, Li HQ*, Hu QH*. Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. Nat Commun 2024, 15, 2083. 一区top期刊 IF:16.6

10. Yin L, Zhang EM, Mao TQ, Zhu YF, Ni SR, Li YH, Liu CX, Fang YF, Ni KX, Lu YH, Zhou MZ*, Li HQ*, Hu QH*. Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. Acta Pharma Sin B 2024, 14, 4360-4377.一区top期刊 IF = 14.7

11. Yehong Li† , Mengze Zhou†, Huanqiu Li†, Chen Dai† , Li Yin, Chunxiao Liu, Yuxin Li, Enming Zhang, Xinli Dong, Hui Ji, Qinghua Hu. Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways. Eur Heart J 2024, 45, 268–283. 一区top期刊IF:38.8

12. Yixin Lv, Zhoudong Zhang, Mengmeng Wang, Yiyun Wang, Mengxi Chen, Jie Jia Yueyue Guo, Kai Wang, Zhi Li, Weipeng Wang*, Huanqiu Li*.Discovery of novel FUT8 inhibitors with promising affinity and in vivo efficacy for colorectal cancer therapy. Bioorgan Chem 2024, 149, 104492. IF:5.1

13. Zhi JY, Yin L, Zhang ZD, Lv YZ, Wu F, Yang Y, Zhang EM, Li HQ*, Lu N, Zhou MZ*,Hu QH*. Network pharmacology-based analysis of Jin-Si-Wei on the treatment of Alzheimer’s disease. J Ethnopharmacol 2024, 319, 117291. IF = 4.8

14. Kai Wanga, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li* Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present). Expert Opin Ther Patents. 2024, 34,611-625 IF = 6.6

15. Yulong Zhao, Zhoudong Zhang, Xiaotian Kong, Kai Wang, Yuxuan Wang, Jie Jia, Huanqiu Li*, Sheng Tian*. Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches. Chem Bio Drug Des 2024,104:e14607.

16. Zhu YF, Zhou MZ, Cheng XY, Wang H, Li YH, Guo YY, Wang YX, Tian S, Mao TQ, Zhang ZD, Li DX, Hu QH*,Li HQ*. Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy. J Med Chem. 2023, 66, 6315-6332.一区top期刊IF:7.8

17. Li YX, Li YH, Zhu YF, Ji W, Wang YX, Dong XL, Zhao X, Wang T, Tian S, Hu QH, Li HQ*. Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. Phytomedicine. 2023, 115, 154851.I一区top期刊IF:7.9

18. Wang MM, Zhang ZD, Chen MX, Lv YX, Tian S, Meng FY, Zhang YW, Guo XQ, Chen Y, Yang M, Li JW, Qiu T, Xu F, Li Z, Zhang Q, Yang J, Sun J, Zhang HJ, Zhang HY, Li HQ* Wang WP*. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer. Cell Death Dis 2023, 14(8): 495. 一区top期刊IF:9.8

19. Zhou M, Wang W, Wang Z, Wang Y, Zhu Y, Lin Z, Tian S, Huang Y, Hu Q*,Li HQ*. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y14R antagonists with anti-gout potential. Eur J Med Chem 227: 113933 (2022). 一区top期刊IF:7.08

20. Lv Y, Zhang Z, Tian S, Wang W, Li HQ*. Advances in the therapeutic potential of inhibitors targeting fucosyltransferases in cancer. Drug Discov Today 2023, 28, 103394.IF:8.3